FDA D.I.S.C.O. Burst Edition: FDA approvals of Tukysa (tucatinib) with trastuzumab for colorectal...

FDA Expert Panel on Testosterone Replacement Therapy for Men

Initiating the Removal of the “Black Box Warning” on Hormone Replacement Therapy

Tobacco Products Scientific Advisory Committee Meeting, October 7, 2025

Conversations on Cancer – Perspectives on Cancer Care Decision-Making Among Older Adults

Medical Device Quality Management System Regulation Risk Management

Medical Device Quality Management System Regulation Design and Development

Good Clinical Practice & Pharmacovigilance Compliance Symposium | D3S08 – Symposium Wrap-up and...

FDA Direct: Removing Black Box Warnings for HRT (Part 2/2)

Good Clinical Practice & Pharmacovigilance Compliance Symposium | D3S05 - (PV): Future of...

GCP & Pharmacovigilance Compliance Symposium | D3S03-1 - (BE): Clinical Study Conduct

Good Clinical Practice & Pharmacovigilance Compliance Symposium | D3S04 - (PV): International...

FDA Direct: Removing Black Box Warnings for HRT (Part 1/2)

Public Meeting: Reauthorization of the Biosimilar User Fee Act

Good Clinical Practice & Pharmacovigilance Compliance Symposium | D3S07 – Q&A Discussion Panel

FDA D.I.S.C.O.: Rucaparib in Ovarian Cancer

FDA Direct: Catching Up on Agency Reforms

November 13, 2025: Pediatric Advisory Committee Meeting (PAC)

Good Clinical Practice & Pharmacovigilance Compliance Symposium | D3S03-2 – Q&A Discussion Panel

FDA Direct: FDA Awards Six National Priority Vouchers

Good Clinical Practice & Pharmacovigilance Compliance Symposium | D3S06 - (PV): Regulatory Updates